A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases

Hepatology International

Volumn 2, Issue 3, 2008, Pages 353-360

  Makhlouf, Hoda A ^a   Helmy, Ahmed ^a,b   Fawzy, Ehab ^a   El Attar, Madiha ^a   Rashed, Hebat Alla G ^a  

^a Assiut University Faculty of Medicine   (Egypt)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Adverse reactions; Drug induced hepatitis; Drug induced liver disease; Pulmonary tuberculosis; Risk factors; Side effects

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COMORBIDITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TUBERCULOSIS;

EID: 51049085584     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9085-y     Document Type: Article

References (50)

1. Cantwell MF, Snider DE, Cauthen GM, Onorato I. Epidemiology of tuberculosis in the United States, 1985 through 1992. J Am Med Assoc 1994;272:535-539
2. Peters BS, Carlin E, Weston RJ, Loveless SJ, Sweeney J, Weber J, et al. Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection. Drug Saf 1994;10:439-454
3. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978;117:991-1001
4. Franks AL, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989;104:151-155
5. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929-932
6. Schaberg T, Rebhan K, Lode H. Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-2030
7. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978;118:461-466
8. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003;41:1226-1232
9. Tanaogllu K. The management of anti-TB drug-induced hepatotoxicity. Int Union Tuberc Lung Dis 2001;5:65-69
10. Benichou C. Criteria for drug-induced liver disorder: Report of an international consensus meeting. J Hepatol 1990;11:272-276
11. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952
12. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521
13. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662
14. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, Salkeen S. Hepatotoxicity with antituberculosis drugs: The risk factors. Pak J Med Sci 2007;23:33-38
15. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986;67:99-108
16. Mehta S. Malnutrition and drugs: Clinical implications. Dev Pharmacol Ther 1990;15:159-165
17. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study. Thorax 1996;51:132-136
18. Gangadharan PRJ. Isoniazid, rifampicin and hepatotoxicity. Am Rev Respir Dis 1986;133:963-965
19. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N -acetyltransferase 2 genotype affects the incidence of INH and RMP-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256-261
20. Shakya R, Rao BS, Shrestha B. Evaluation of risk factors for anti tuberculosis drug induced hepatotoxicity in Nepalese population. Ann Pharmacother 2004;38:1074-1079
21. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for all antituberculosis drugs-induced hepatitis. Hepatology 2002;35:883-889
22. Steele MA, Burk RF, DesPrez RM. Hepatitis with INH and RMP: A meta-analysis. Chest 1991;99:465-471
23. Villor AF, Sopena B, Villor JF. The influence of risk factors on the severity of antituberculosis drug induced hepatotoxicity. Int J Tuberc Lung Dis 2004;8:1499-1505
24. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005;26:462-464
25. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Can Med Assoc J 2002;167:131-136
26. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-1265
27. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-930
28. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N -acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997;34:758-760
29. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury: I. Performance characteristics of laboratory tests. Clin Chem 2000;46:2027-2049
30. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-1311
31. Attri S, Rana SV, Vaiphie K, Katyal R, Sodhi CP, Kanwar S, et al. Protective effect of N -acetylcysteine in isoniazid induced hepatic injury in growing rats. Indian J Exp Biol 2001;39:436-440
32. Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attri S, Thakur S, et al. Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition. J Biochem Toxicol 1996;11:139-146
33. Marvin W. Impacts of gender on drug responses. Drug Top 1998;591-600
34. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919
35. LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis 2005;9:501-506
36. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: A 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-123
37. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid: A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133:1072-1075
38. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71:1113-1120
39. Ferebee S, Mount F. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1969;85:490-510
40. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978;59:13-32
41. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short course chemotherapy trial 21: Effectiveness, toxicity, and acceptability. Ann Intern Med 1990;112:397-406
42. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: Results during chemotherapy. Br J Dis Chest 1981;75:141-153
43. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment. Tuber Lung Dis 1996;77:37-42
44. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477
45. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002;6:699-705
46. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-206
47. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-504
48. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997;12:87-91
49. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-1876
50. Snider DE, Caras G. Isoniazid-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992;145:494-497